Recent updates

  • 14 Feb 2020FDA requests withdrawal of lorcaserin from the marketTopic:Obesity in adults
  • 13 Feb 2020The WHO declares international public health emergencyTopic:COVID-19
  • 12 Feb 2020EMA's safety committee recommends restricting the use of ondansetron during the first trimester of pregnancyTopic:Nausea and vomiting in pregnancy
  • 19 Dec 2019Update on Ebola outbreak in the Democratic Republic of CongoTopic:Ebola virus infection
  • 19 Nov 2019US guidelines on community-acquired pneumonia updatedTopic:Community-acquired pneumonia
  • 30 Oct 2019EMA’s safety committee recommends a 4-week limit for use of high-strength estradiol creamsTopic:Menopause
  • 30 Oct 2019EMA’s safety committee recommends a 4-week limit for use of high-strength estradiol creamsTopic:Urinary tract infections in women
  • 22 Oct 2019FDA warns direct-acting antivirals can cause serious liver injury in patients with advanced liver diseaseTopic:Hepatitis C
  • 13 Sep 2019FDA approves liraglutide for use in children ≥10 years with type 2 diabetesTopic:Type 2 diabetes in children
  • 09 Apr 2019Intravenous artesunate now first-line treatment for severe malaria in the USTopic:Malaria infection
  • 14 Nov 2018First-in-class treatment approved in the US for relapsed or refractory hairy cell leukemiaTopic:Hairy cell leukemia
  • 20 Sep 2018CDC alerts clinicians to a 'dramatic rise' in overdose deaths from fentanyl and its analogsTopic:Opioid overdose
  • 13 Jul 2018European Medicines Agency (EMA) strengthens measures to avoid use of valproate medicines in pregnancyTopic:Bipolar disorder in children